"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy.
about
The critical role of the central nervous system (pro)renin receptor in regulating systemic blood pressureThe ubiquitous mineralocorticoid receptor: clinical implicationsAldosterone, a new appreciation of its role in heart failure.A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patientsHeart failure and the brain: new perspectives.The role of angiotensin II receptor blockers in the treatment of heart failure patients.Aldosterone receptor antagonists: focus on eplerenone.Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease.The therapeutic potential of angiotensin II receptor blockers in the treatment of heart failure.AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.Protective effects of angiotensin II interruption: evidence for antiinflammatory actions.Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?Carvedilol in the treatment of elderly patients with chronic heart failure.Relations of biomarkers representing distinct biological pathways to left ventricular geometryRole of aldosterone in the remnant kidney model in the rat.Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.Review article: eplerenone: an underused medication?Upstream effect for atrial fibrillation: still a dilemma?New approaches to the treatment of nephropathy in diabetes.Aldosterone receptor antagonists: current perspectives and therapiesFinerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.Differential effects of antihypertensive drugs on neurohormonal activation: insights from a population-based sample.Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials.Effect of eplerenone, a selective aldosterone blocker, on the development of diabetic nephropathy in type 2 diabetic rats.PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathyRationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT).Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure.Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats.Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats.Potential beneficial as well as detrimental effects of chronic treatment with lisinopril and (or) spironolactone on isolated hearts following low-flow ischemia in normal and infarcted rats.Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension.Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results.Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis.Beneficial effect of replacing of angiotensin-converting enzyme inhibitor with angiotensin II antagonist for heart failure patients.Outpatient management of chronic heart failure.The effect of angiotensin-converting enzyme inhibitor use on bone loss in elderly Chinese.Anaesthesia for Conn's syndrome.Clinical Trials Report: Cardiovascular & Renal: Ongoing and planned clinical trials in chronic heart failure and left ventricular dysfunction
P2860
Q26750465-31095D7D-EE14-46DB-A5C0-F7635E09C245Q26861721-511B0EE1-5A22-4293-82F1-5BBABF991605Q34041396-90F452AD-3910-49E3-AA4F-AD8179E0DD20Q34075463-9D56A3E6-7FED-4827-BBD1-E32164C159DBQ35046024-5AA60C34-0047-48B6-8316-F55F3E0E0FFAQ35056228-9DBC2655-D4AD-47DE-A6C6-CE884DE189EEQ35080685-7D9E3F79-6BD5-43EF-8349-BA9B15FE32E3Q35580143-C05899CA-45E0-4E95-84B3-2EC311DEE550Q35688228-BFBA166C-A9DF-45D9-A3BE-BA2DD8211918Q35925706-566A4391-6465-4C02-953B-F69FBCED5CCBQ36242608-0B82B705-F070-4EC7-8595-F937633E3F85Q36257966-57CE2B08-EEF7-4173-8FAF-D608E5297D74Q36392987-59DD8824-85B9-499B-AA0C-1C1BA3837AA7Q36437145-88344BA8-98F1-4604-AC34-1ABBAA184A41Q36892905-147BE600-E886-4C76-817A-BB2AF2DC7E89Q37355268-EDAC589B-1799-4B19-B26A-59ABB400AB46Q37358980-DD208D8A-9E4D-4B19-95ED-5A8FF4FD7B7AQ37574913-3436CE2D-2BA3-4C7E-8960-73ADCA739540Q37793666-D81C44DE-E37F-4956-8DD5-10B56D5E5A17Q37804417-59CD5B67-441B-44BF-B09F-860A6A58A52BQ37899907-A2F2FB13-8386-466A-998F-55C2117245EDQ38120241-92D41EDE-FB50-4F7E-9280-95633ABDD6D1Q38533385-A8D43121-47DD-4B76-9369-DBCA36DAC4C3Q39490174-387D57E1-D2F0-4B43-8684-D720DB0F5CBBQ41875563-5D7E24AC-85EE-40F7-A3CC-8FD08363DE8CQ41970822-D9EAAEDF-9644-4F8B-9D59-2C9E944F2355Q42672479-B220EE81-B250-4C45-9D58-56CA4A996626Q43534981-8DB80CA7-07D7-49BF-8102-317CECB18278Q43773190-0DF7BCDB-FB47-4A5F-A809-93B469853028Q44279118-12C5F081-0D50-4220-9A40-59A1AB63014DQ44361936-8DD81ED2-5CD9-4D8A-B0A3-B3BBDDF04E23Q44653714-14D039BF-0A8E-49C9-B9A6-AF18484D8621Q45981857-E93BB389-3BC5-4B04-B10D-132A10BA2FC7Q46160863-8B18EFAF-62B2-4956-BFF8-645700C2D430Q47125921-D3451E2A-4E7A-425A-944F-7F36FB7140B1Q48513826-9C567BA7-A0B6-4398-9E19-782F9FA7CC3EQ50998627-47AB8C3C-F69F-4727-89EE-4B3F9074BC53Q51329093-DED2C4B0-D35C-471E-850D-66925DE5A6C7Q51451352-9B1EC3FA-BFCE-4A57-A4AB-FE97BFA6FA45Q57396425-9EED8C2F-73BC-4EED-A6B2-78C6BB795855
P2860
"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
"Escape" of aldosterone produc ...... tor: implications for therapy.
@en
type
label
"Escape" of aldosterone produc ...... tor: implications for therapy.
@en
prefLabel
"Escape" of aldosterone produc ...... tor: implications for therapy.
@en
P356
P1476
"Escape" of aldosterone produc ...... tor: implications for therapy.
@en
P2093
P304
P356
10.1007/BF00877755
P577
1995-02-01T00:00:00Z